Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 272R |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Renal |
| Current Generation (* indicates number of generations grown in Castrate host) |
11 |
| Average PDX Generation Time (days +/- SEM) | 189 ± 32 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 272R |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 272R | CDKN1B | -1.015 | 0.989 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 272R | CHD7 | 1.024 | 4.067 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 272R | MSH2 | -1.011 | 0.992 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 272R | MSH2 | -11.112 | 9.039e-04 | Homdel | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 272R | MYC | 1.024 | 4.067 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 272R | MYC | 0.812 | 3.511 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
Clinical Information
| Sample Number | 272R |
|---|---|
| Sample Site | Prostate |
| Sample source | Radical prostatectomy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | 9 |
| Primary Gleason Score | 4 |
| Secondary Gleason Score | 5 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | 5 |
| Tumour Grade | pT3bN1 |
| D'Amico Risk Classification | 7 |
| Tumour Volume (in cc) | 20.2 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 272 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 9.2 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 272R |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 272R | BCORL1 | 592 | 0.94 | Frameshift variant | '12/12 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | DMD | 106 | 0.91 | Frameshift variant | '40/79 | . | 34 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | BAX | 171 | 0.8 | Frameshift variant | '3/5 | 0.0001061 | 23.8 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | PRKDC | 725 | 0.69 | Missense variant | '29/87 | . | 26.6 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | NKX3-1 | 2365 | 0.67 | Inframe deletion | '2/2 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | LTBP4 | 243 | 0.56 | Missense variant | '11/34 | 0.0001098 | 28 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | MET | 455 | 0.53 | Stop gained | '21/21 | 1.22E-05 | 38 | Uncertain significance | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | RNF43 | 1135 | 0.52 | Frameshift variant | '8/9 | 0 | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | WNT4 | 1047 | 0.51 | Missense variant | '2/5 | . | 33 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | SOX9 | 641 | 0.51 | Missense variant | '3/3 | . | 27.1 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | SMAD2 | 361 | 0.51 | Frameshift variant | '11/11 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | CYP2D6 | 411 | 0.5 | Missense variant | '2/9 | 1.59E-05 | 29.1 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | OGDH | 399 | 0.5 | Missense variant | '7/23 | . | 33 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | RXRG | 303 | 0.5 | Missense variant | '3/10 | 4.48E-05 | 25.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | LRP2 | 297 | 0.5 | Missense variant | '46/79 | . | 24.2 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | NOTCH3 | 206 | 0.49 | Missense variant | '33/33 | 1.24E-05 | 29.1 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | MTOR | 399 | 0.49 | Missense variant | '42/58 | . | 29.8 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | FANCA | 995 | 0.48 | Missense variant | '26/43 | 8.22E-06 | 23.2 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | FGFR4 | 1026 | 0.48 | Missense variant | '16/18 | . | 29.1 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | TRIM33 | 667 | 0.48 | Missense variant | '11/20 | 3.66E-05 | 27 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | SPEN | 1306 | 0.48 | Frameshift variant | '11/15 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | CACNA1H | 218 | 0.47 | Missense variant | '32/35 | 1.79E-05 | 25.5 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | PDGFRB | 855 | 0.47 | Missense variant | '13/23 | 4.18E-06 | 24.8 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | PBRM1 | 129 | 0.47 | Frameshift variant | '9/30 | 0 | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | ZFHX3 | 1259 | 0.46 | Frameshift variant | '9/10 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | CAPN1 | 263 | 0.46 | Missense variant | '17/21 | 4.47E-05 | 32 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | CAPN1 | 263 | 0.46 | Missense variant | '17/21 | 4.47E-05 | 32 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | AKT3 | 345 | 0.44 | Missense variant | '14/14 | . | 32 | Pathogenic/likely pathogenic | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | ZFHX3 | 1265 | 0.43 | Frameshift variant | '9/10 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | CACNA1H | 175 | 0.42 | Missense variant | '9/35 | 2.76E-05 | 22.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 272R | ABL1 | 1551 | 0.34 | Missense variant | '11/11 | 1.63E-05 | 29.8 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
No information in Drug dosing Table